GET THE APP

Re-irradiation in cancer - Can amifostine help us?
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Re-irradiation in cancer - Can amifostine help us?


25th WORLD CANCER CONFERENCE

October 19-21, 2017 | Rome, Italy

Oliver Micke, Jens Buntzel and Henno Welgemood

Franziskus Hospital Bielefeld, Germany
S�������¼dharz Klinikum Nordhausen, Germany
Clinigen Group plc, UK

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

A second irradiation course has been established for the treatment of recurrent head and neck cancer since more than 5 decades. 24-month survival rates are limited to 30-40%. Severe acute and late toxicities are observed in up to 50% of all treated patients. Does selective cytoprotection with amifostine offer a way to reduce the high toxicity profile? We reanalyzed the data of three earlier published mono-centric studies which had combined re-irradiation of a solid tumor with the application of 500 mg amifostine IV before daily radiotherapy. 42/53 patients received re-irradiation because of head and neck cancer disease. 11 have had other solid tumors (rectal cancer 5, cervical cancer 2, endometrial cancer 2, uterus sarcoma 1, and prostate cancer 1). All head and neck cancer patients received additional chemotherapy for radio-sensitizing. The therapy was possible in all patients without serious adverse events due to amifostine. The combination of chemo- and radiotherapy was possible in all treated patients. The total irradiation doses were >110 Gy for both courses. Acute mucosal and skin toxicities (mucositis, stomatitis, diarrhea, dermatitis, cystitits and proctitis) were reduced to grade 1 / 2 level in 49/53 patients. Grade 3 /4 toxicities were seen in only <10% (n=4). No objective data were available for late toxicities and survival. In conclusion, we suggest initiating new research on the combination of amifostine and re-irradiation of solid tumors. We await the reduction of acute toxicity and positive impact on late toxicity profile as well as effect of irradiation in this situation.

Biography :

Oliver Micke has completed his PhD from Muenster University Hospital in 2006. He is Head of the Department for Radiotherapy and Radiation Oncology at Franziskus Hospital Bielefeld since 2006. In addition, he is the Medical Director of Franziskus Hospital Bielefeld, a premier teaching hospital of the Medical University of Hanover (MHH). He has published more than 200 papers in reputed national and international journals and has been serving as Reviewer as well as an Editorial Board Member of repute.

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward